- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04551625
Colonic Motility in Patients With Diabetes
Assessment of Colonic Motility in Patients With Diabetes Using High Resolution Colonic Manometry and 3D-Transit.
Background:
Gastrointestinal (GI) symptoms are overrepresented in patients with diabetes mellitus (DM) and often have a major impact on quality of life. Typical symptoms of diabetic enteropathy include abdominal pain, nausea, vomiting, diarrhoea, constipation, faecal incontinence, and bloating. Bowel symptoms in DM are usually caused by widespread dysfunction of the GI tract, but the exact pathophysiology remains incompletely understood. Within recent years, new methods for detailed assessment of GI motility have been developed. Hence, the electromagnetic 3D-Transit system is a safe, non-invasive method for detailed description of GI motility. The system tracks the exact position of an ingested electromagnetic capsule through the entire GI tract and provides detailed information on both regional transit- and contraction patterns. High Resolution Colonic Manometry (HRCM) allows extremely detailed description of contraction patterns in the colon. The HRCM is however an invasive method, as the catheter is placed during colonoscopy. HRCM has not previously been performed on diabetic patients and 3D-Transit has only been used sparingly.
Study Objectives:
The purpose of this study is to obtain detailed description of colonic contractions in patients with DM and gastrointestinal symptoms, especially during fast and after meals.
Hypothesis:
- Patients with DM and GI symptoms have reduced high-amplitude, antegrade contractions in the colon when compared to healthy controls (HRCM).
- Patients with DM and GI symptoms have reduced long, fast mass-movements when compared to healthy controls (3D-Transit).
- The contractile response to a meal is reduced in patients with symptoms of diabetic enteropathy when compared to healthy controls.
Materials and methods:
20 patients with DM type 1 or 2 and GI symptoms will be investigated simultaneously HCRM and the 3D-Transit capsule. Data will be compared to the healthy from another study (CIV-19-05-028726). A colonoscopy is performed to install the HRCM catheter and place two 3D-Transit capsules within the colon. For 24 hours, the participants lie in a bed in the research lab while pressure changes from the HRCM catheter are recorded and the 3D-Transit capsules are followed through the gastrointestinal system.
Perspectives:
The study will add to the very limited data available on colonic dysfunction in DM.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Ditte S Iversen, MD
- Phone Number: 40517858
- Email: Dittiver@rm.dk
Study Contact Backup
- Name: Klaus Krogh, MD, ph.d.
- Phone Number: 23385937
- Email: Klaukrog@rm.dk
Study Locations
-
-
-
Aarhus, Denmark, 8200
- The Department og Hepatology and gastroenterology, Aarhus University Hospital
-
Contact:
- Ditte S Iversen, MD
- Phone Number: 40517858
- Email: Dittiver@rm.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Type 1 or 2 diabetes (at least 3 years since diagnosis)
- Age between 18 and 70
- Gastrointestinal symptoms with a weighted and combined symptomscore >2,3 (assessed with The Gastrointestinal Symptom Rating Scale and The Gastroparesis Cardinal Symptom Score).
- Psychologically able to give an informed content.
Exclusion Criteria:
- Known gastrointestinal disease
- Intake of medication with known effects on the motility patterns in the gastrointestinal system.
- Dysregulated hyperthyroidism or hypothyroidism.
- Any disease known to cause gastroparesis (Parkinson's disease, scleroderma, etc.)
- Pacemaker/ICD
- A scheduled MRI scan within 4 weeks after trial initiation.
- Abdominal circumference >140cm
- Pregnancy and lactation
- Unable to follow the scheduled program in the trial due to mental illness or instability.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
High amplitude, antegrade contractions assessed with HRCM
Time Frame: All 24 hours of HRCM and 3D-Transit recording
|
Quantity, amplitude and duration of the high amplitude, antegrade propagating contractions accessed with HRCM, when compared to healthy controls.
|
All 24 hours of HRCM and 3D-Transit recording
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long, fast mass-movements assessed with 3D-Transit
Time Frame: All 24 hours of HRCM and 3D-Transit recording.
|
Quantity and length of the long, fast mass-movements assessed with 3D-Transit, when compared to healthy controls.
|
All 24 hours of HRCM and 3D-Transit recording.
|
Distance of capsule movement.
Time Frame: All 24 hours of HRCM and 3D-Transit recording.
|
How do the length of a pressure change measured by HRCM correlate with the distance covered in long fast antegrade movements determined with the 3D-Transit system (cm).
|
All 24 hours of HRCM and 3D-Transit recording.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Klaus Krogh, MD, ph.d., Overall scientific leadership of the protocol
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRCM_3DT_DM
- EUDRAMED: CIV-20-05-032844 (Other Identifier: Danish Medicines Agency)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on High Resolution Colonic Manometry and 3D-Transit system.
-
Janne Ladefoged FassovAalborg University HospitalUnknownHealthy | Colonic MotilityDenmark
-
Medical University of WarsawMedtronic - MITGCompletedChildren | Anorectal DisorderPoland
-
Medical University of WarsawMedtronic - MITGCompletedChildren | Hirschsprung Disease | Anorectal Disorder | Anorectal AtresiaPoland
-
Assistance Publique Hopitaux De MarseilleCompletedAnal Incontinence or ConstipationFrance
-
Russian Academy of Medical SciencesState Scientific Centre of Coloproctology, Russian Federation; Federal Research...RecruitingHealthy SubjectsRussian Federation
-
University of California, San FranciscoNot yet recruiting
-
Russian Academy of Medical SciencesRecruiting
-
Hospices Civils de LyonCompletedConstipation | Fecal Incontinence | Anorectal DisorderFrance
-
Hull University Teaching Hospitals NHS TrustRecruitingCough | Asthma | Copd | ILDUnited Kingdom
-
Sudarshan JadcherlaNot yet recruitingFeeding Disorder Neonatal